title: Safety and Efficacy of Anti-TNFα Treatment in Crohn's Disease Patients with Abdominal Abscesses.
abstract: OBJECTIVE
  It is estimated that up to 30% of CD patients develop abdominal abscesses; the management of active luminal CD in such patients represents a clinical challenge. The aim of this study is to assess the safety of biologics in patients with Crohn's disease and abdominal abscesses treated with percutaneous drainage and/or broad-spectrum antibiotics.
  
  
  METHODS
  We performed a retrospective review of the clinical charts of consecutive Crohn's disease patients with abdominal abscesses treated with anti-TNFα therapy attended in our institution.
  
  
  RESULTS
  12 patients were finally included in the study. All were treated with broad-spectrum antibiotic and biological therapy (anti-TNF); indication of anti-TNFα therapy was moderate to severe activity of CD in all of them. Percutaneous drainage of the abscess was performed in 7 of the 12 patients. No complications were observed during a mean follow-up of 37,8 (16-71) months, including abscess volume increase, enterocutaneous fistula, soft tissue infections, bacteraemia, or need for emergency surgery.
  
  
  CONCLUSIONS
  In addition to conventional treatment, the use of anti-TNFα therapy in Crohn's disease patients with abdominal abscesses seems to be safe. Usefulness of this approach has to be validated in larger cohorts.
authors.forename: Luis
authors.initials: L
authors.lastname: Ibáñez-Samaniego
authors.forename: Fernando
authors.initials: F
authors.lastname: Díaz-Fontenla
authors.lastname: Miranda-Bautista José
authors.forename: Carmen
authors.initials: C
authors.lastname: Acosta
authors.forename: Irene
authors.initials: I
authors.lastname: Barceló
authors.forename: Virginia
authors.initials: V
authors.lastname: Flores
authors.forename: Mikel
authors.initials: M
authors.lastname: Echenagusía
authors.forename: Fernando
authors.initials: F
authors.lastname: Camúñez
authors.forename: Alicia
authors.initials: A
authors.lastname: Díaz-Redondo
authors.forename: Ignacio
authors.initials: I
authors.lastname: Marín-Jiménez
authors.forename: Luis
authors.initials: L
authors.lastname: Menchén
mesh_terms: D018784:Abdominal Abscess / Q000175:diagnosis / Q000276:immunology / Q000628:therapy*; D000328:Adult; D000900:Anti-Bacterial Agents / Q000009:adverse effects / Q000627:therapeutic use*; D000893:Anti-Inflammatory Agents / Q000009:adverse effects / Q000627:therapeutic use*; D001688:Biological Products / Q000009:adverse effects / Q000627:therapeutic use*; D003424:Crohn Disease / Q000150:complications / Q000175:diagnosis / Q000188:drug therapy* / Q000276:immunology; D004322:Drainage / Q000009:adverse effects; D057286:Electronic Health Records; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D012189:Retrospective Studies; D012307:Risk Factors; D012720:Severity of Illness Index; D013997:Time Factors; D016896:Treatment Outcome; D014409:Tumor Necrosis Factor-alpha / Q000037:antagonists & inhibitors* / Q000276:immunology; D055815:Young Adult
chemical_list: D000900:Anti-Bacterial Agents; D000893:Anti-Inflammatory Agents; D001688:Biological Products; D014409:Tumor Necrosis Factor-alpha